The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa).
 
Steven P Angus
No Relationships to Disclose
 
Timothy Stuhlmiller
No Relationships to Disclose
 
Noah Sciaky
No Relationships to Disclose
 
Xin Chen
No Relationships to Disclose
 
Rashid Naim
No Relationships to Disclose
 
Maki Tanioka
No Relationships to Disclose
 
Kristalyn K. Gallagher
No Relationships to Disclose
 
Andres Forero
Research Funding - Genentech/Roche (Inst)
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Research Funding - Genentech
 
Alastair Mark Thompson
Travel, Accommodations, Expenses - Novartis (I)
 
Rashmi Krishna Murthy
Consulting or Advisory Role - Daiichi Sankyo; Genentech
Research Funding - Merrimack (Inst); Oncothyreon (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Oncothyreon
 
Xiaping He
No Relationships to Disclose
 
Charles M. Perou
Leadership - Bioclassifier; GeneCentric
Stock and Other Ownership Interests - Bioclassifier; GeneCentric
Consulting or Advisory Role - Bioclassifier; G1 Therapeutics; GeneCentric
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent
 
Shelton Earp
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst)
 
Gary L. Johnson
Research Funding - Genentech/Roche (Inst)